Innoviva Inc
INVAHealthcare|Biotechnology|USA
$22.23
+0.04 (+0.20%)
DCF (FCF)
$42.29
Tangible Book
$15.56
Graham Number
$41.06
Earnings Power
$26.78
Upcoming Data Readouts (4)
Jan 2028
Est. completion
Early P1Septic Shock
Comparison of Angiotensin II to Standard Dose Vasopressors on Change in Arterial Elastance
NCT07568275n=30
May 2028
Est. completion
P1Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
A Study to Assess Sulbactam-durlobactam in Pediatric Patients With Acinetobacter Baumannii-calcoaceticus Complex Infection
NCT06801223n=48
Jan 2029
Est. completion
Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)
A Study to Assess the Safety and Risk of Hypersensitivity Reactions of Sulbactam-durlobactam in Adults With Acinetobacter Baumannii-calcoaceticus (ABC) Complex Infection
NCT06746883n=100
Feb 2029
Est. completion
P2Complicated Intra-abdominal Infections (cIAI)
A Study to Evaluate the Safety and Tolerability of Eravacycline in Pediatric Patients Aged 8 to 17 With Complicated Intra-abdominal Infections (cIAI)
NCT06794541n=35